Table 2. Activation dependent transactivation of ECR1-525 in Jurkat T cells.

Treatment	ECR1_525+control	ECR1_525+p65	ECR1_525+NFATc2/p
Medium	1% (±0.2)	1.2% (±1.1)	0.7% (±0.5)
PMA	1.5% (±0.6)	13.4% (±3.1)	1.5% (±0.5)
Iono	0.6% (±0.2)	0.3% (±1.1)	1.3% (±1.8)
PHA	1.3% (±1.1)	4.4% (±2.7)	1% (±1.0)
CD3	0.8% (±0.5)	5.9% (±1.4)	0.6% (±0.4)
CD28	0.8% (±0.4)	2.1% (±1.5)	0.7% (±0.7)
PMA/iono	2.5% (±1.5)	20.7% (±2.6)	2.3% (±1.0)
PMA/PHA	2.7% (±0.6)	14.5% (±3.6)	2.5% (±1.1)
CD3/CD28	1.2% (±0.4)	6.3% (±1.6)	0.7% (±0.1)

Jurkat T cells were electroporated using 2 µg ECR1_525 in combination with 1 µg of either p65 cDNA, NFATc2/p cDNA or as a control empty pCIneoHA vector. After electroporation, cells were divided and treated for 22 h with the indicated stimuli. Prior to flow cytometry measurement, the cells were stained with 1 µg/ml 7-AAD to distinguish dead cells from the living population. The table summarizes the percentages of d2EGFP expressing cells and the respective SD of three independent experiments.